ArticleCancer immunology research2020
Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV
Article in Cancer immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Patient-Derived Xenograft Models in Cervical Cancer: A Systematic Review.International journal of molecular sciences · 2021Pooled it
- A Spike-Linked HPV16 E7 DNA Vaccine Induces Potent Antitumor and Anti-Spike Immune Responses.International journal of molecular sciences · 2026Article
- LILRB4 shapes an immunosuppressive microenvironment to drive cervical cancer progression through tumor-infiltrating myeloid cell expansion and CD8Cellular and molecular life sciences : CMLS · 2026Article
- PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1-KDM5C-IL6 Axis in ccRCC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Divergent immune ecosystems in HPV-associated and HPV-independent lower anogenital tract malignancies.Frontiers in immunology · 2026Review
- The role of SIGLEC9 in immunosuppression and prognosis in cervical cancer.Clinics (Sao Paulo, Brazil) · 2025Article
- Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stages.Immuno-oncology technology · 2025Article
- Targeting immune microenvironment in cervical cancer: current research and advances.Journal of translational medicine · 2025Review
- Advances and obstacles of T cell-based immunotherapy in gynecological malignancies.Molecular cancer · 2025Review
- Molecular, cellular, biochemical, and rehabilitative insights into exercise interventions for gynecological cancer prevention and survivorship: a narrative review.Journal of ovarian research · 2025Review
- HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine.Cancer discovery · 2025Article
- Review
- Convergent inducers and effectors of T cell paralysis in the tumour microenvironment.Nature reviews. Cancer · 2025Review
- T cell subsets in cervical cancer tumor microenvironment: advances and therapeutic opportunities.Frontiers in immunology · 2025Review
- The immune microenvironment of cancer of the uterine cervix.Histology and histopathology · 2024Review
- Intraepithelial CD15 infiltration identifies high-grade anal dysplasia in people with HIV.JCI insight · 2024Article
- Effects of intratumoral microbiota on tumorigenesis, anti-tumor immunity, and microbe-based cancer therapy.Frontiers in oncology · 2024Review
- Role of the tumor microenvironment in the lymphatic metastasis of cervical cancer (Review).Experimental and therapeutic medicine · 2023Review
- Clinical, morphologic and molecular heterogeneity of HPV-associated oropharyngeal cancer.Oncogene · 2023Review
- Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.The Journal of clinical investigation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
Cancers induced by human papillomaviruses (HPV) should be responsive to immunotherapy by virtue of expressing the immunogenic oncoproteins E6/E7. However, advanced forms of cervical cancer, driven by HPV, are poorly responsive to immune response-enhancing treatments involving therapeutic vaccination against these viral neoantigens. Leveraging a transgenic mouse model of HPV-derived cancers, K14HPV16/H2b, we demonstrated that a potent nanoparticle-based E7 vaccine, but not a conventional "liquid" vaccine, induced E7 tumor antigen-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.